亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

阿卡波糖

 
 
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2014-02-09 09:04
 

湖北大華偉業醫藥化工有限公司

企業會員第13年
資料未認證
保證金未繳納
詳細說明

阿卡波糖 
英文名稱:acarbose 
中文別名:O-4,6-雙脫氧-4[[(1S,4R,5S,6S)4,5,6-三羥基-3-(羥基甲基)-2-環己烯]氨基]-(-D-吡喃 葡糖基(1→4)-O-)-D-吡喃葡糖基(1→4)-D-吡喃葡萄糖 
CAS:56180-94-0 
EINECS號:260-030-7 
分子式: C25H43NO18 
分子量: 645.61232 
用途 :用于胰島素依賴型和非胰島素依賴型糖尿病的治療。
中文名稱: 阿卡波糖 CAS:56180-94-0
別名:抑葡萄糖苷酶 ,阿卡波糖 ,拜糖平,拜糖蘋
英文名稱: Acarbose
質量標準:EP6
含量:99%
包裝規格:10KG/袋
分子式: C25H43NO18
分子量: 645.6
酸度 5.5 - 7.5 比旋度 +168 - +183°
吸收值  ≤0.15(波長425nm處)
干燥失重 ≤4.0%
熾灼灰份 ≤0.2% 重金屬 ≤20PPM
總雜質 ≤1.0% 含量 95.0%- 102.0%
質量標準:EP5.1 /usp28
包 裝:5kg/Drum
性狀:本品為白色或微黃色無定形粉末
作用與用途:阿卡波糖一種新型口服降糖藥。在腸道內競爭性抑制葡萄糖甙水解酶。降低多糖及蔗糖分解成葡萄糖,使糖的吸收相應減緩,因此可具有使飯后血糖降低的作用。 一般單用,或與其它口服降血糖藥,或胰島素合用。配合餐飲,治療胰島素依賴型或非依賴型糖尿病
 



Tel 18702770802
舉報收藏 0評論 0
更多>本企業其它產品
5-硝基水楊酸 L-谷氨酰胺 奧沙利鉑 奧扎格雷 L-肌肽 α-環糊精 阿莫西林
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |